1、OssaNova™人工骨修复材料 注册证编号：2502543ĐKLH/BYT-HTTB 产品名称：人工骨修复材料 证件有效期：2025.07.16-永久有效 证券代码：688613 证券简称：奥精医疗 公告编号：2025-038 奥精医疗科技股份有限公司 自愿披露关于公司产品在越南获得注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于2024年12月向越南卫生部 递交了公司人工骨修复材料的注册申报资料。公司于近日收到越南卫生部通知，公 司人工骨修复材料获得批准。现将相关情况公告如下： 一、注册证内容 奥精医疗科技股份有限公司董事会 2025年7 月 22 日 产品分类：D类（高风险医疗器械） 二、医疗器械基本情况 1、OssaNova™人工骨修复材料 本次获得越南注册证的OssaNova™人工骨修复材料是基于奥精医疗具有完全自主 知识产权的体外仿生矿化技术研发和生产的一种仿生矿化胶原人工骨修复材料，在 组成成分和微观结构上均对人体天然骨组织高度仿生。产品用于口腔 ...

奥精医疗公告，公司于2024年12月向越南卫生部递交了人工骨修复材料的注册申报资料，近日收到通 知，该材料获得批准。OssaNova 人工骨修复材料是基于公司具有完全自主知识产权的体外仿生矿化技 术研发和生产的一种仿生矿化胶原人工骨修复材料。产品用于口腔科或整形外科无植骨禁忌的骨缺损修 复，植入体内后能够在引导骨再生的同时被新生骨组织爬行替代。本次公司产品在越南获得注册证，是 公司海外业务拓展的重要组成部分，将对公司产品在海外的销售起到一定的推动和促进作用。 ...

Core Insights - The Chinese dental beauty industry is experiencing rapid growth, driven by increasing consumer demand for oral health and aesthetics, with a market size expected to exceed 78.5 billion yuan by 2025 [1][16][25] - The industry is characterized by three main features: explosive demand from 718 million oral disease patients, innovation in supply with a 25% penetration rate of invisible orthodontics, and rapid market expansion with a CAGR of 15.9% from 2018 to 2023 [1][12][16] Industry Overview - Dental beauty focuses on improving the appearance, shape, and alignment of teeth through non-invasive or minimally invasive techniques, aiming to unify natural aesthetics and functionality [2] - The industry includes various segments such as teeth whitening, veneer restoration, crown restoration, orthodontics, and gum shaping [2] Development Drivers - **Consumer Upgrade and Demand Change**: The shift from essential treatment to aesthetic consumption is evident, with over 60% of Gen Z viewing teeth whitening as key to confidence [4][16] - **Technological Innovation**: Breakthroughs in materials science and digital technology are reshaping industry standards, with AI aesthetic design and 3D printing significantly enhancing service efficiency [6][25] - **Policy and Capital Synergy**: Government initiatives like "Healthy China 2030" and increased financing are facilitating industry growth and standardization [7][25] - **Silver Economy and Niche Market Rise**: The aging population is driving demand for dental aesthetics, with 35% of spending on implants and aesthetic restorations coming from those aged 50 and above [8][25] Industry Chain - The industry chain exhibits high collaboration and vertical integration, with upstream focusing on high-value consumables and digital equipment, while domestic brands are rapidly replacing foreign ones in the mid-range market [9][20] Market Size and Growth - The market size grew from 28.56 billion yuan in 2018 to 59.82 billion yuan in 2023, with a projected growth to over 78.5 billion yuan by 2025 [16][18] Competitive Landscape - The industry features a multi-tiered competition structure, with foreign brands dominating the high-end market and domestic brands rapidly expanding in the mid-range and low-end markets [20][22] - The top five brands in the implant sector hold nearly 70% market share, while the invisible orthodontics market is dominated by two major players [20][22] Future Trends - **Technological Integration**: The industry is moving towards full-cycle intelligent management, integrating AI, 3D printing, and biological materials [25][26] - **Market Layering and Downstream Expansion**: The competition is characterized by high-end precision, mid-range differentiation, and low-end accessibility, with community health stations expanding rapidly [27][28] - **Ecosystem Reconstruction and Regulatory Upgrades**: The industry is evolving towards a cross-sector integration of healthcare, technology, and consumer services, with increased regulatory oversight [28]

Summary of Key Points Core Viewpoint - Aojing Medical (688613) has shown a slight increase in stock price, reflecting ongoing adjustments in its fundraising projects and governance decisions [1]. Company Performance - As of July 11, 2025, Aojing Medical's stock closed at 18.31 yuan, up 0.22% from the previous week [1]. - The stock reached a weekly high of 18.77 yuan on July 7 and a low of 17.7 yuan on July 10 [1]. - The company's current total market capitalization is 2.509 billion yuan, ranking 113th out of 126 in the medical device sector and 4692nd out of 5149 in the overall A-share market [1]. Corporate Governance - Aojing Medical held its first extraordinary general meeting of 2025 on July 11, 2025, in Beijing, with 89 attendees representing 26,135,097 shares, accounting for 19.0755% of the voting rights [1]. - The meeting approved adjustments to certain fundraising project implementation subjects, locations, and sub-projects, with 98.7191% of votes in favor, 1.2186% against, and 0.0623% abstaining [1]. - The meeting was witnessed by lawyers from Beijing Zhonglun Law Firm, confirming that all procedures and results complied with relevant laws and regulations [1].

Core Viewpoint - The legal opinion letter confirms that the procedures for convening and holding the 2025 first extraordinary general meeting of shareholders of Aojing Medical Technology Co., Ltd. comply with relevant laws and regulations [1][5][6]. Group 1: Meeting Procedures - The company published the notice for the extraordinary general meeting on June 26, 2025, which included details such as meeting time, voting methods, and agenda items, with a notice period of 15 days before the meeting [2][3]. - The meeting was held on July 11, 2025, at a specified location, and was presided over by the company's chairman, Eric Gang Hu [3]. Group 2: Attendance and Qualifications - A total of 89 shareholders and authorized agents attended the meeting, holding 26,135,097 shares, which represents a significant portion of the voting rights as of the registration date [5][6]. - The qualifications of the attendees and the convenor of the meeting were verified to be in accordance with the relevant laws and the company's articles of association [5][6]. Group 3: Voting Procedures and Results - The voting process combined both on-site and online methods, with results being counted and announced immediately after the meeting [7]. - The meeting approved the agenda items as listed in the notice, and there were no objections raised regarding the voting results [7]. Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including convening, attendance, and voting procedures, were conducted in compliance with applicable laws and regulations, rendering the results valid [5][7].

1 法律意见书 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席本 次股东大会人员和召集人的资格、会议表决程序及表决结果是否符合《公司法》 《股东会规则》等相关法律、法规、规章、规范性文件及《公司章程》的规定发 表意见，并不对会议审议的议案内容以及该等议案所表述的事实或数据的真实性 及准确性发表意见。本所仅根据现行有效的中国法律问题发表意见，而未对有关 会计、审计和资产评估等非法律专业事项发表意见，亦未对非中国法律问题发表 意见。 本所同意将本法律意见书作为本次股东大会的公告材料，随同其他会议文件 一并报送有关机构并公告。本法律意见书仅供公司为本次股东大会之目的而使用， 未经本所书面同意，本法律意见书不得用于任何其他目的。 北京市中伦律师事务所 关于奥精医疗科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：奥精医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受奥精医疗科技股份有限公 司（以下简称"公司"）委托，指派律师见证公司 2025 年第一次临时股东大会 （以下简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-037 奥精医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 7 月 11 日 （二） 股东大会召开的地点：北京市大兴区庆丰西路 69 号 35 号楼 3 层 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 89 | | --- | --- | | 普通股股东人数 | 89 | | 2、出席会议的股东所持有的表决权数量 | 26,135,097 | | 普通股股东所持有表决权数量 | 26,135,097 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 19.0755 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 19.0755 | （五） ...

Company Summary - Aojing Medical (688613) reported a significant increase in sales volume of its core product "Gaojin," with a year-on-year growth of 93.54% in 2024, selling 1.4714 million cm3 compared to 760,300 cm3 in 2023 [1] - In Q1 2025, the sales volume of "Gaojin" further accelerated, achieving a remarkable growth of 174% [1] - The price of artificial bone products, including "Gaojin," decreased significantly due to centralized procurement, with prices dropping from 1,000-1,500 RMB/cm3 to 320-340 RMB/cm3, allowing more patients to access these materials [1] Industry Overview - The domestic bone repair market is in a phase of continuous expansion, with significant growth potential for artificial bone, particularly biomimetic mineralized collagen materials [3] - The market size of bone repair materials in China was approximately 2.58 billion RMB in 2023, with a projected compound annual growth rate (CAGR) of 14.5% from 2022 to 2028 [3] - Artificial bone materials are becoming the primary clinical application consumables in the bone repair field, overcoming the limitations of autologous and natural bone [3]

Core Viewpoint - The report highlights the financial performance and operational challenges faced by Aojing Medical Technology Co., Ltd. in 2024, including a significant decline in revenue and net profit due to price reductions from centralized procurement and increased competition in the medical device market [2][11]. Summary by Sections Business Performance - In 2024, the company's main business revenue was impacted by a decrease in the ex-factory price of artificial bones due to centralized procurement, leading to a net profit of -12.66 million yuan, a year-on-year decrease of 123.35% [2][11]. - The revenue from the neurosurgery product "Cerebrum" was 13.85 million yuan, down 70.07% year-on-year [2][11]. - The company reported a significant increase in sales volume of its orthopedic product "Guanjin," with a total sales volume of 1.4714 million cm³ in 2024, a 93.54% increase from 2023 [5][11]. Product Analysis - The centralized procurement led to a drop in the clinical terminal price of artificial bones from 1,000-1,500 yuan/cm³ to 320-340 yuan/cm³, which increased the accessibility of artificial bones for patients [5][11]. - The oral product "Zhibei" saw a substantial revenue increase due to new high-quality distributor partnerships, contributing 30.84 million yuan, accounting for 78.44% of its total revenue [5][16]. Regional Sales Concentration - The company's sales are primarily concentrated in East and North China, where it has established a strong presence with over 200 hospitals using its products [7][11]. - The concentration in these regions is attributed to the availability of advanced medical resources and the acceptance of innovative medical products [7][11]. Sales Expenses - Sales expenses increased significantly due to the expansion of the sales team and marketing efforts related to the centralized procurement and the acquisition of HumanTech Dental [9][11]. - The increase in travel expenses was driven by a higher number of terminal hospitals and the need for market support activities [9][11]. Financial Challenges - The company's performance turned from profit to loss due to several factors, including reduced profit margins from centralized procurement, declining neurosurgery product revenue, and increased operating costs [11][10]. - The overall gross margin for the orthopedic product "Guanjin" fell to 72.84%, a decrease of 11.03 percentage points year-on-year [10][11]. Acquisition of HumanTech Dental - The acquisition of HumanTech Dental was completed in 2024, with a goodwill of 24.62 million yuan, although the acquired company has not yet achieved profitability [20][21]. - The integration of HumanTech Dental's operations is aimed at expanding the company's market presence in the dental implant sector [21][22]. Accounts Receivable - The accounts receivable increased by 13.31% year-on-year, with the company extending credit terms to some high-quality distributors to support their sales efforts [17][19]. - The company has a bad debt provision ratio of 13.55%, indicating a cautious approach to credit risk management [17][19].

01 c 立信会计师事务所（特殊普通合伙） 关于奥精医疗科技股份有限公司 2024 年年度报告的信息披露监管 间询函的回复 信会师函字[2025]第 ZB113 号 立信会计师事务所(特殊普通合伙) 关于奥精医疗科技股份有限公司 2024 年年度报告的信息披露监管问询函的回复 信会师函字[2025]第 ZB113 号 上海证券交易所科创板公司管理部: 根据贵所出具的《关于奥精医疗科技股份有限公司 2024 年年度报告的信息 披露监管问询函》(以下简称"问询函")的有关要求,立信会计师事务所(特 殊普通合伙）(以下简称"年审会计师"或"我们")作为奥精医疗科技股份有 限公司（以下简称"奥精医疗"或"公司"）的 2024 年年度审计报告会计师事 务所,对问询函中提到的需要年审会计师发表意见的问题进行了认真核查,具体 回复内容如下: 说明:本回复报告中若出现总计数尾数与所列数值总和尾数不符的情况, 均为四舍五入所致。 问题 -- 关于主营业务与经营业绩。年报披露，（1）2024 年公司主营业务收入 20,043.09 万元,同比下滑 8.24%,其中骨科、神经外科业务收入分别同比下滑 3.83%、70.07%，口腔 ...